2011 ASH Program Book - American Society of Hypertension
2011 ASH Program Book - American Society of Hypertension
2011 ASH Program Book - American Society of Hypertension
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
AtCor Medical, Inc. (USA)<br />
Contact: Beth Boyer<br />
One Pierce Place, Suite 225W<br />
Itasca, IL 60143<br />
Phone: 630-228-8871<br />
Fax: 630-228-8872<br />
Email: info@atcormedical.com<br />
Website: www.atcormedical.com<br />
Booth Number: 1106<br />
AtCor Medical developed and markets SphygmoCor® systems,<br />
the global gold standard in noninvasive assessment <strong>of</strong> central<br />
blood pressure and arterial stiffness. Featured in over 600<br />
published studies, SphygmoCor systems are used worldwide in<br />
leading medical centers, physicians’ <strong>of</strong>fices, in research and in<br />
pharmaceutical clinical trials.<br />
Daiichi Sankyo, Inc.<br />
Contact: Ann Marie Bermudez<br />
2 Hilton Court<br />
Parsippany, NJ 07054<br />
Phone: 973-944-2600<br />
Fax: 973-944-2891<br />
Email: abermudez@dsi.com<br />
Website: www.dsi.com<br />
Booth Number: 1200<br />
Daiichi Sankyo, Inc. (DSI), headquartered in Parsippany, NJ,<br />
is the U. S. subsidiary <strong>of</strong> Daiichi Sankyo Co., Ltd., a global<br />
pharmaceutical company. DSI was formed in 2006 from the<br />
integration <strong>of</strong> two leading pharmaceutical companies, Sankyo<br />
Pharma, Inc. and Daiichi Pharmaceutical Corporation.<br />
Its team <strong>of</strong> nearly 3,000 U.S. employees is dedicated to the<br />
creation and supply <strong>of</strong> innovative pharmaceutical products to<br />
address the diversified, unmet medical needs <strong>of</strong> patients. DSI<br />
concentrates in the therapy areas <strong>of</strong> hypertension, thrombosis,<br />
dyslipidemia, diabetes and acute coronary syndrome. Clinical<br />
development and regulatory activities are headquartered at<br />
Daiichi Sankyo Pharma Development in Edison, NJ. Visit<br />
www.dsi.com.<br />
160